Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2016

 

APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware		001-36370		59-3553710
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
14193 NW 119 th Terrace Suite 10 Alachua, Florida				32615
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: [phone]  

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

---

 

Item 2 .0 2.    Results of Operations and Financial Condition

On September 12, 2016, Applied Genetic Technologies Corporation issued a press release entitled “AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016.”  The press release is furnished as Exhibit 99.1.

Item 9.01.   Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated September 12, 2016, entitled “AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016”

 

 

 

2

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

			APPLIED GENETIC TECHNOLOGIES CORPORATION
Date:   September 12, 2016			By:	/s/ Lawrence E. Bullock
				Lawrence E. Bullock
				Chief Financial Officer

 

 

3

---

 

Exhibit Index

Exhibit No.	Description
99.1	Press release dated September 12, 2016, entitled “AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016”

 

 

 

4